Debulking the urate load to feel better

Journal of Rheumatology

Volumn 39, Issue 7, 2012, Pages 1311-1313

  Richette, Pascal ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PEGLOTICASE; PLACEBO; URATE;

AGE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; EDITORIAL; GENDER; GOUT; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; OUTCOME ASSESSMENT; PATIENT REPORTED OUTCOMES; PATIENT SATISFACTION; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; REFRACTORY PERIOD; RHEUMATOID ARTHRITIS; SHORT FORM 36; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL;

FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; PHYSICAL FITNESS; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; URATE OXIDASE;

EID: 84863535697     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120427     Document Type: Editorial

References (21)

1. Richette P, Bardin T. Gout. Lancet 2010;375:318-28.
2. Kleinman NL, Brook RA, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, et al. The impact of gout on work absence and productivity. Value Health 2007;10:231-7. (Pubitemid 47077244)
3. Strand V, Crawford B, Singh J, Choy E, Smolen JS, Khanna D. Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases. Ann Rheum Dis 2009;68:1800-4.
4. Becker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009;36:1041-8.
5. Reach G. Treatment adherence in patients with gout. Joint Bone Spine 2011;78:456-9.
6. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24. (Pubitemid 44620440)
7. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007;46:1372-4.
8. Fels E, Sundy JS. Refractory gout: What is it and what to do about it? Curr Opin Rheumatol 2008;20:198-202. (Pubitemid 351339893)
9. Richette P, Briere C, Hoenen-Clavert V, Loeuille D, Bardin T. Rasburicase for tophaceous gout not treatable with allopurinol: An exploratory study. J Rheumatol 2007;34:2093-8. (Pubitemid 47548217)
10. Garay RP, El-Gewely MR, Labaune JP, Richette P. Therapeutic perspectives on uricases for gout. Joint Bone Spine 2012 Feb 24. [Epub ahead of print]
11. Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: Two randomized controlled trials. JAMA 2011; 306:711-20.
12. Sherman MR, Williams LD, Sobczyk MA, Michaels SJ, Saifer MG. Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconjug Chem 2012;23:485-99.
13. Strand V, Khanna D, Singh JA, Forsythe A, Edwards NL. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: Evidence from phase III randomized controlled trials. J Rheumatol 2012;39:1450-7.
14. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: Evidence from randomized controlled trials. Am J Manag Care 2008;14:234-54.
15. Richette P. Lesinurad, a uricosuric agent for gout. Thomson Reuters Pharma. Available from: https://www.thomson-pharma.com/portal/page/portal/ Reports/DRUG%20TABBED%20REPORT/DRUG-03?-dummy=y&resultType= citedDrugs&isNewSearch=Y¶mNames=referenceid¶mNames= dbsource¶mValues=1267128
16. ten Klooster PM, Vonkeman HE, van de Laar MA. Disability due to gouty arthritis. Curr Opin Rheumatol 2012;24:139-44.
17. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis 2008;67:1310-6.
18. Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N, et al. Outcome domains for studies of acute and chronic gout. J Rheumatol 2009;36:2342-5.
19. Ten Klooster PM, Oude Voshaar MA, Taal E, van de Laar MA. Comparison of measures of functional disability in patients with gout. Rheumatology 2011;50:709-13.
20. Colwell HH, Hunt BJ, Pasta DJ, Palo WA, Mathias SD, Joseph-Ridge N. Gout Assessment Questionnaire: Initial results of reliability, validity and responsiveness. Int J Clin Pract 2006;60:1210-7. (Pubitemid 44375441)
21. Strand V, Boers M, Idzerda L, Kirwan JR, Kvien TK, Tugwell PS, et al. It's good to feel better, but it's better to feel good, and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol 2011;38:1720-7.